MPNs | Clinical

August 30, 2022

In the interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the FDA approval of pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. He also discussed the FIGHT-203 trial, and possibilities for pemigatinib in the future.

August 26, 2022

Following promising preclinical data, the phase 1 IMproveMF trial in myelofibrosis doses its first patient with imetelstat and ruxolitinib.

August 21, 2022

Results from the MANIFEST study of pelabresib and ruxolitinib in myelfibrosis are positive. The phase MANIFEST-2 study continue to explored the combination in JAK inhibitor–naïve patients with myelofibrosis.

August 18, 2022

During a Targeted Oncology case-based roundtable event, Angela G. Fleischman, MD, PhD, discussed how to approach treatment of a 68-year-old patients with myelofibrosis.

August 17, 2022

Results from MOMENTUM and other phase 3 studies will be reviewed by the FDA as the regulatory body considers approval of momelotinib for patients with myelofibrosis and anemia.

August 15, 2022

Raajit Rampal, MD, PhD, discusses the current treatment landscape for patients with myelofibrosis.

July 31, 2022

Raajit Rampal, MD, PhD, discusses his recommended approach to assessing and treating patients with myelofibrosis.

July 16, 2022

Gabriela Hobbs, MD, discusses the unmet needs that have yet to be filled in the post-myeloproliferative neoplasm acute leukemia space.

July 15, 2022

In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, discussed phase 3 MOMENTUM study and how it has impacted the clinical trial development of momelotinib for the treatment of patients with myelofibrosis.

July 07, 2022

During a case-based roundtable event, David A. Rizzieri, MD, discussed the case of a 68-year-old patient with myelofibrosis.